Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00375492
Status:
COMPLETED
Last Update Posted:
2015-04-07
First Post:
2006-09-11
Brief Title:
Effect on Weight Loss of Exenatide Versus Placebo
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin sulfonylurea or metformin plus a sulfonylurea Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None